These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756 [TBL] [Abstract][Full Text] [Related]
5. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia. Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of l-DOPA-induced dyskinesia. Fisone G; Bezard E Int Rev Neurobiol; 2011; 98():95-122. PubMed ID: 21907084 [TBL] [Abstract][Full Text] [Related]
8. Levodopa in the early treatment of Parkinson's disease. Murata M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036 [TBL] [Abstract][Full Text] [Related]
9. Role of surgery in the treatment of motor complications. Metman LV; O'Leary ST Mov Disord; 2005; 20 Suppl 11():S45-56. PubMed ID: 15822076 [TBL] [Abstract][Full Text] [Related]
10. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease]. Maurel F; Lilliu H; Le Pen C Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770 [TBL] [Abstract][Full Text] [Related]
11. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479 [TBL] [Abstract][Full Text] [Related]
12. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008 [TBL] [Abstract][Full Text] [Related]
13. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549 [TBL] [Abstract][Full Text] [Related]
15. [Physiopathology of the dyskinesias induced by L-dopa]. Grandas F; López-Ariztegui N Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]
17. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Prashanth LK; Fox S; Meissner WG Int Rev Neurobiol; 2011; 98():31-54. PubMed ID: 21907082 [TBL] [Abstract][Full Text] [Related]
18. [Dyskinesia caused by L-DOPA]. Derkinderen P; Vidailhet M Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668 [TBL] [Abstract][Full Text] [Related]
19. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Rascol O Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400 [No Abstract] [Full Text] [Related]
20. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399 [No Abstract] [Full Text] [Related] [Next] [New Search]